Operating Lease, Right-of-Use Asset of ALPINE IMMUNE SCIENCES, INC. from 31 Dec 2018 to 31 Mar 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of lessee's right to use underlying asset under operating lease.
Summary
ALPINE IMMUNE SCIENCES, INC. quarterly Operating Lease, Right-of-Use Asset in USD history and change rate from 31 Dec 2018 to 31 Mar 2024.
  • ALPINE IMMUNE SCIENCES, INC. Operating Lease, Right-of-Use Asset for the quarter ending 31 Mar 2024 was $7,317,000, a 9.1% decline year-over-year.
Source SEC data
View on sec.gov
Operating Lease, Right-of-Use Asset, Quarterly (USD)
Operating Lease, Right-of-Use Asset, YoY Quarterly Change (%)

ALPINE IMMUNE SCIENCES, INC. Quarterly Operating Lease, Right-of-Use Asset (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q1 2024 $7,317,000 -$734,000 -9.1% 31 Mar 2024 10-Q 09 May 2024 2024 Q1
Q4 2023 $7,510,000 -$709,000 -8.6% 31 Dec 2023 10-Q 09 May 2024 2024 Q1
Q3 2023 $7,697,000 -$684,000 -8.2% 30 Sep 2023 10-Q 14 Nov 2023 2023 Q3
Q2 2023 $7,877,000 -$662,000 -7.8% 30 Jun 2023 10-Q 14 Aug 2023 2023 Q2
Q1 2023 $8,051,000 -$640,000 -7.4% 31 Mar 2023 10-Q 11 May 2023 2023 Q1
Q4 2022 $8,219,000 -$618,000 -7% 31 Dec 2022 10-K 20 Mar 2024 2023 FY
Q3 2022 $8,381,000 -$599,000 -6.7% 30 Sep 2022 10-Q 14 Nov 2022 2022 Q3
Q2 2022 $8,539,000 -$579,000 -6.4% 30 Jun 2022 10-Q 11 Aug 2022 2022 Q2
Q1 2022 $8,691,000 -$560,000 -6.1% 31 Mar 2022 10-Q 12 May 2022 2022 Q1
Q4 2021 $8,837,000 -$564,000 -6% 31 Dec 2021 10-K 23 Mar 2023 2022 FY
Q3 2021 $8,980,000 -$554,000 -5.8% 30 Sep 2021 10-Q 10 Nov 2021 2021 Q3
Q2 2021 $9,118,000 -$556,000 -5.7% 30 Jun 2021 10-Q 10 Aug 2021 2021 Q2
Q1 2021 $9,251,000 -$587,000 -6% 31 Mar 2021 10-Q 13 May 2021 2021 Q1
Q4 2020 $9,401,000 -$584,000 -5.8% 31 Dec 2020 10-K 17 Mar 2022 2021 FY
Q3 2020 $9,534,000 -$1,296,000 -12% 30 Sep 2020 10-Q 12 Nov 2020 2020 Q3
Q2 2020 $9,674,000 -$1,629,000 -14% 30 Jun 2020 10-Q 11 Aug 2020 2020 Q2
Q1 2020 $9,838,000 +$9,235,000 +1532% 31 Mar 2020 10-Q 14 May 2020 2020 Q1
Q4 2019 $9,985,000 +$9,985,000 31 Dec 2019 10-K 18 Mar 2021 2020 FY
Q3 2019 $10,830,000 30 Sep 2019 10-Q 14 Nov 2019 2019 Q3
Q2 2019 $11,303,000 30 Jun 2019 10-Q 13 Aug 2019 2019 Q2
Q1 2019 $603,000 31 Mar 2019 10-Q 09 May 2019 2019 Q1
Q4 2018 $0 31 Dec 2018 10-Q 13 Aug 2019 2019 Q2
* An asterisk sign (*) next to the value indicates that the value is likely invalid.